Credit Suisse Group Raises Teladoc Health (NYSE:TDOC) Price Target to $225.00

Teladoc Health (NYSE:TDOC) had its price target lifted by Credit Suisse Group from $165.00 to $225.00 in a research note issued to investors on Thursday, The Fly reports. They currently have a neutral rating on the health services provider’s stock.

Other equities analysts also recently issued research reports about the stock. Stephens began coverage on shares of Teladoc Health in a research note on Monday, July 6th. They issued an overweight rating and a $250.00 price target for the company. Zacks Investment Research downgraded shares of Teladoc Health from a buy rating to a hold rating and set a $171.00 price target for the company. in a research note on Thursday, May 28th. Stifel Nicolaus boosted their price target on shares of Teladoc Health from $135.00 to $144.00 and gave the stock a hold rating in a research note on Thursday, April 30th. Royal Bank of Canada boosted their price target on shares of Teladoc Health from $200.00 to $235.00 and gave the stock an outperform rating in a research note on Thursday. Finally, Cowen restated a buy rating and issued a $197.00 price target on shares of Teladoc Health in a research note on Wednesday, July 8th. Fifteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $195.04.

Shares of NYSE TDOC opened at $237.63 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.14 and a quick ratio of 6.14. Teladoc Health has a 52-week low of $54.58 and a 52-week high of $240.00. The business’s 50 day moving average is $207.13 and its two-hundred day moving average is $158.76.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.11). The firm had revenue of $241.03 million during the quarter, compared to analysts’ expectations of $220.49 million. Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 10.23%. The firm’s revenue for the quarter was up 85.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) EPS. Sell-side analysts expect that Teladoc Health will post -1.41 EPS for the current fiscal year.

In other news, SVP Andrew Turitz sold 2,778 shares of the company’s stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $200.00, for a total value of $555,600.00. Following the completion of the sale, the senior vice president now directly owns 6,793 shares of the company’s stock, valued at $1,358,600. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jason N. Gorevic sold 40,000 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $170.26, for a total transaction of $6,810,400.00. Following the completion of the sale, the chief executive officer now directly owns 711,283 shares of the company’s stock, valued at $121,103,043.58. The disclosure for this sale can be found here. Insiders sold 189,977 shares of company stock valued at $36,248,032 in the last 90 days. 3.42% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the company. Baldwin Brothers Inc. MA raised its holdings in shares of Teladoc Health by 2.9% in the second quarter. Baldwin Brothers Inc. MA now owns 2,820 shares of the health services provider’s stock valued at $538,000 after buying an additional 80 shares during the last quarter. Citizens Financial Group Inc RI raised its holdings in shares of Teladoc Health by 20.4% in the first quarter. Citizens Financial Group Inc RI now owns 489 shares of the health services provider’s stock valued at $76,000 after buying an additional 83 shares during the last quarter. Cypress Asset Management Inc. TX raised its holdings in Teladoc Health by 1.2% during the second quarter. Cypress Asset Management Inc. TX now owns 7,040 shares of the health services provider’s stock worth $1,344,000 after purchasing an additional 85 shares in the last quarter. Wealthstreet Investment Advisors LLC raised its holdings in Teladoc Health by 1.5% during the first quarter. Wealthstreet Investment Advisors LLC now owns 6,752 shares of the health services provider’s stock worth $1,047,000 after purchasing an additional 100 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Teladoc Health by 2.3% during the second quarter. Parallel Advisors LLC now owns 4,517 shares of the health services provider’s stock worth $862,000 after purchasing an additional 101 shares in the last quarter. 97.14% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: What is meant by buying and selling pressure?

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.